# IMU Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imu-biosciences

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.imubiosciences.com
- Total disclosed funding: $66M
- Latest round: Series A (Jun 2, 2026)
- Investors on record: 5

## About

Founded in 2019 and headquartered in London, United Kingdom, the company was co-founded by Adam Laing, Tom Hayday, and Mario Cantero. Melio Health Ltd., trading under the name IMU Biosciences, operates as a biotech company that develops an immunological atlas to treat a range of human health and disease. In June 2026, IMU Biosciences raised GBP 40 million in series A funding co-led by Molten Ventures and IQ Capital, with participation from British Business Bank and Meltwind Advisory. 

The firm develops and offers an immune discovery platform using AI/ML (artificial intelligence/machine learning) to develop precision medicines. The platform aids in the advancement of translational research and accelerates the drug development process in areas of cell therapy, immuno-oncology, transplantation, and autoimmunity.

The company plans to use the June 2026 funding to support operational expansion, develop its clinical platform and infrastructure, and advance clinical programs including stem cell transplant, solid organ transplant, and cancer immunotherapy research.

## Funding rounds

- Series A, Jun 2, 2026, $54M — Molten Ventures, IQ Capital, Meltwind Advisory, British Business Bank
- Series A, Sep 27, 2023, $12M — Molten Ventures, LifeX Ventures

## Investors

- Molten Ventures (https://capitalatlas.ai/funds/molten-ventures) — Series A
- LifeX Ventures (https://capitalatlas.ai/funds/lifex-ventures) — Series A
- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Series A
- Meltwind Advisory (https://capitalatlas.ai/funds/meltwind-advisory) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A